Gilead Sciences, Inc. announced today that Jacqueline K. Barton, Ph.D., has been appointed to the company’s Board of Directors. She previously served on Gilead’s Scientific Advisory Board from 1989 to 2007.
Dr. Barton is the John G. Kirkwood and Arthur A. Noyes Professor of Chemistry and Norman Davidson Leadership Chair of the Division of Chemistry and Chemical Engineering at the California Institute of Technology, where she has been a faculty member for nearly 30 years. She served on the Board of Directors of the Dow Chemical Company from 1993 to 2017, and currently is a member of the Materials Science Advisory Committee of DowDuPont, Inc. She founded and served on the Board of GeneOhm Sciences, Inc., a molecular diagnostic company acquired by Becton Dickinson and Company. She is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society. In 2011, Dr. Barton received the National Medal of Science for her discovery of new chemistry of the DNA helix.
“We are very pleased to welcome Jacqueline Barton to the Board of Directors of Gilead Sciences,” said John Milligan, Ph.D., President and Chief Executive Officer, Gilead Sciences. “Jackie is one of the most decorated chemists in America and was awarded the Priestley Medal from the American Chemical Society, its highest honor. Her deep knowledge of scientific discovery in both academic and industry settings will help guide our long-term strategy as Gilead continues to translate science into better solutions for patients.”
Source: Gilead Sciences
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.
On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.
General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.